Pulmonary Medicine, published by HINDAWI LTD, stands as a prestigious open-access journal since 2010, dedicated to advancing the field of pulmonary and respiratory medicine. Located in Egypt, this journal is indexed with an ISSN of 2090-1836 and an E-ISSN of 2090-1844, and it has attained a commendable Q2 ranking in both the miscellaneous medicine and pulmonary health categories, indicative of its significant impact and quality. With an impressive Scopus ranking of #15 out of 155 in the pulmonary and respiratory medicine category, the journal is positioned in the 90th percentile, highlighting its relevance and contribution to ongoing research. The journal aims to publish high-quality original research, reviews, and clinical studies that address pressing issues in pulmonary health, making it a vital resource for researchers, clinicians, and students seeking to enhance their understanding and practice in respiratory medicine. By embracing an open-access model, Pulmonary Medicine provides a platform for disseminating knowledge, fostering collaboration, and driving innovation within the global scientific community.

Expert Review of Respiratory Medicine is a leading journal published by Taylor & Francis Ltd, dedicated to advancing the field of respiratory medicine through evidence-based research and comprehensive reviews. With a robust ISSN of 1747-6348 and an E-ISSN of 1747-6356, the journal disseminates essential insights into pulmonary and respiratory health, ranking an impressive #33 in Medicine - Pulmonary and Respiratory Medicine on Scopus, reflecting its significant contribution to this discipline. Established in 2007 and extending its reach through 2024, Expert Review of Respiratory Medicine serves as a crucial resource for professionals and researchers dedicated to improving respiratory health outcomes. Though not designated as an open-access journal, its impactful articles are pivotal in shaping clinical practices and guiding future research in respiratory medicine and related fields, including public health and immunology. By engaging with this journal, readers can stay abreast of the latest developments and critically evaluate advancements in respiratory care.

THORAX is a premier academic journal dedicated to advancing knowledge in the field of Pulmonary and Respiratory Medicine. Published by the esteemed BMJ Publishing Group in the United Kingdom, this journal has been a pivotal resource for researchers and clinicians since its inception in 1946. With a remarkable ranking of #6 out of 155 in its category, THORAX holds a prestigious position within the top 4% of its field, as indicated by its 2023 Q1 quartile classification and a strong Scopus ranking. The journal focuses on publishing high-quality research, reviews, and clinical studies that are essential for understanding respiratory diseases and their management. Although it is not an open-access journal, THORAX provides vital contributions to the academic community, fostering dialogue and innovation in pulmonary medicine. As it approaches its converged years, concluding in 2024, researchers, professionals, and students are encouraged to explore its rich repository of knowledge, while engaging with the most current advancements in the field.

Advances in Respiratory Medicine is a distinguished open-access journal published by MDPI, focusing on the latest research and developments in the field of pulmonary and respiratory medicine. Launched in 2015 and operating out of Switzerland, this journal aims to advance scientific discourse and knowledge by providing a platform for researchers, clinicians, and health professionals. With an impressive ISSN of 2451-4934 and an E-ISSN of 2543-6031, it has made its mark in the academic community, reflected by its impact factor and recognition in the Q3 category for Pulmonary and Respiratory Medicine as of 2023. The journal enjoys a ranking of #95 out of 155 in Scopus within its category, providing authors with visibility and the potential for impactful dissemination of their research. Open access since 2022, it ensures that findings are readily available to all, fostering collaboration and innovation across disciplines. With a commitment to quality and rigor, Advances in Respiratory Medicine invites contributions that push the boundaries of existing knowledge, making it an invaluable resource for anyone dedicated to enhancing respiratory health.

Pediatric Pulmonology is a leading journal published by Wiley, dedicated to advancing the field of pediatric respiratory medicine. With an impressive impact factor and a commitment to excellence since its inception in 1985, this quarterly publication reaches researchers, clinicians, and healthcare professionals interested in the latest findings and practices concerning pediatric pulmonary health. The journal has achieved notable rankings in prestigious databases, including Q1 in Pediatrics, Perinatology, and Child Health, and Q2 in Pulmonary and Respiratory Medicine, reflecting its high-quality contributions to the field. Celebrated for its rigorous peer-review process, Pediatric Pulmonology serves as a vital platform for disseminating significant research, clinical studies, and innovative approaches to the management of respiratory conditions in infants, children, and adolescents. This journal not only provides valuable insights but also fosters collaboration among professionals dedicated to enhancing the care and outcomes for young patients. Access to this resource is available through institutional subscriptions, further ensuring widespread dissemination of crucial research findings.

Tuberkuloz ve Toraks (Tuberculosis and Thorax) is a distinguished journal published by the TURKISH ASSOCIATION OF TUBERCULOSIS AND THORAX located in Turkey. Serving as a pivotal platform for researchers and practitioners in the fields of Critical Care, Intensive Care Medicine, and Pulmonary and Respiratory Medicine, this journal has been disseminating vital research since 2003 and is committed to advancing knowledge and clinical practices related to tuberculosis and thoracic diseases. Although currently not an Open Access publication, its relevance is underscored by its rankings within Scopus, including a Q3 category in Critical Care and Intensive Care Medicine and a Q4 in Pulmonary and Respiratory Medicine, reflecting its significant contributions to the academic community. With a mission to foster the exchange of innovative ideas and encourage rigorous scholarly discourse, Tuberkuloz ve Toraks plays an essential role in addressing pressing health challenges associated with respiratory ailments and remains an invaluable resource for researchers, health professionals, and students dedicated to improving outcomes in thoracic health.

Tuberculosis and Respiratory Diseases is a leading open-access journal published by THE KOREAN ACADEMY OF TUBERCULOSIS & RESPIRATORY DISEASES, dedicated to disseminating knowledge in the fields of infectious diseases and pulmonary medicine. Since its inception in 1980, the journal has undergone significant growth, currently recognized in the elite Q2 category for both Infectious Diseases and Pulmonary and Respiratory Medicine as of 2023. With an impact factor reflecting its esteemed position—ranked 52nd in its category—it serves as a vital resource for researchers and healthcare professionals seeking cutting-edge insights, studies, and advancements in the management and treatment of respiratory diseases, particularly tuberculosis. The journal is committed to providing open access to its content since 2013, ensuring that critical research is available to scholars worldwide, fostering collaboration and innovation in the global fight against respiratory illnesses.

Jornal Brasileiro de Pneumologia is a pivotal open-access journal in the field of Pulmonary and Respiratory Medicine, published by SOC BRASILEIRA PNEUMOLOGIA TISIOLOGIA. Established in 2004, this esteemed publication has become a significant platform for researchers, health professionals, and students in Brazil and beyond, facilitating the exchange of innovative ideas and vital research findings. The journal is indexed in Scopus and is recognized in the 2023 category quartiles as Q3, ranking 86 out of 155 in its field with a corresponding 44th percentile. This reflects its growing influence and commitment to advancing knowledge concerning respiratory health. With a mission to disseminate high-quality research, the journal aims to foster advancements in clinical practice and improve outcomes in pulmonary diseases, making it an essential resource for those dedicated to enhancing the quality of care in respiratory medicine. For those seeking comprehensive access to critical studies and reviews in this domain, the Jornal Brasileiro de Pneumologia remains an invaluable asset.

RESPIRATION is a prestigious journal dedicated to advancing knowledge in the field of Pulmonary and Respiratory Medicine, with a commitment to publishing high-quality, peer-reviewed research. Established in 1944 and published by KARGER in Switzerland, this journal has maintained an exemplary impact within the scientific community, currently holding a Q1 ranking in the 2023 category for Pulmonary and Respiratory Medicine, placing it among the top 18% of journals in its field. With an ISSN of 0025-7931 and an E-ISSN of 1423-0356, RESPIRATION provides a platform for researchers and professionals to disseminate original studies, reviews, and clinical cases that shape contemporary understanding and treatment of respiratory diseases. The journal's rigorous standards for publication ensure that it remains a vital resource for the latest innovations and findings. As part of its mission, RESPIRATION seeks to bridge the gap between clinical practice and research, fostering multidisciplinary collaboration and enhancing patient outcomes. The journal is readily accessible, ensuring that vital research reaches a broad audience of healthcare professionals and academic scholars globally.

Therapeutic Advances in Respiratory Disease is a prestigious open-access journal published by SAGE Publications Ltd, based in the United Kingdom. Since its inception in 2007, it has established itself as a leading platform for the dissemination of cutting-edge research in the fields of pulmonary and respiratory medicine and pharmacology. With an impressive impact factor and ranking—showing it is in the Q1 quartile in both Pharmacology (medical) and Pulmonary and Respiratory Medicine as of 2023—the journal's commitment to high-quality research is evident. In 2023, it ranks #32 out of 155 in Pulmonary and Respiratory Medicine and #57 out of 272 in Medical Pharmacology, positioning it in the 79th percentile across these disciplines. Open access since 2018, the journal ensures that its valuable content is readily accessible to a global audience of researchers, healthcare professionals, and students, facilitating the rapid exchange of knowledge that is crucial in the ever-evolving landscape of respiratory health. The journal's objectives include advancing understanding of respiratory diseases through innovative research and promoting the development of therapeutic strategies that improve patient outcomes, making it an essential resource for those dedicated to respiratory medicine.